Glucophage

Glucophage is a prescription medication whose active ingredient is metformin hydrochloride, a biguanide oral antidiabetic drug. It is supplied in tablet form (strength and dosage form may vary) and is marketed in the European Union. Glucophage works by lowering hepatic glucose production and improving peripheral insulin sensitivity, making it a standard option for managing type 2 diabetes mellitus. It is often prescribed as part of a comprehensive lifestyle and medication plan.

Glucophage is indicated for the treatment of several aspects of type 2 diabetes management.

- As monotherapy in patients whose diet and exercise alone are insufficient to control blood glucose. - In combination with other oral antidiabetic agents (e.g., sulfonylureas, DPP‑4 inhibitors) to improve glycemic control. - As an adjunct to insulin therapy to reduce the required insulin dose. - For patients who are overweight or obese, helping with weight management while controlling glucose. - May be considered in pre‑diabetes to delay progression to diabetes (off‑label in some regions).

Side effects of Glucophage vary in frequency and severity; they are commonly categorized as mild or serious.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Decreased appetite. - Mild headache. - Weight loss.

Serious: - Lactic acidosis, characterized by rapid breathing, muscle pain, or unusual fatigue. - Severe hypoglycemia when combined with insulin or sulfonylureas. - Hepatotoxicity presenting as jaundice or elevated liver enzymes. - Skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before starting Glucophage, certain precautions and warnings should be reviewed to ensure safe use.

- Assess renal function; contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Monitor liver enzymes; avoid use in patients with acute or chronic hepatic disease. - Evaluate for conditions predisposing to hypoxia (e.g., heart failure, recent myocardial infarction) due to lactic acidosis risk. - Adjust dose in elderly patients or those with reduced gastrointestinal absorption. - Discontinue before any radiographic study using iodinated contrast agents; resume only after renal function is re‑checked. - Counsel patients on recognizing symptoms of lactic acidosis and to seek immediate medical attention. - Advise consistent dietary habits to minimize gastrointestinal side effects.

Glucophage can interact with other medicines, affecting its efficacy or safety.

Avoid: - Iodinated contrast agents used for radiographic procedures. - Cimetidine, which can raise metformin levels. - Didanosine and other nucleoside reverse transcriptase inhibitors that increase lactic acidosis risk.

Use with caution: - Sulfonylureas or insulin, due to additive hypoglycemia risk. - Diuretics that may impair renal clearance. - Alcohol consumption, which can predispose to lactic acidosis.